【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMe...【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。展开更多
Objective： To evaluate the protective effects of Reduning Injection （热毒宁注射液, RDN）, a patent Chinese medicine, on lipopolysaccharide （LPS）-induced acute lung injury （ALl） in rats and its underlying mechani...Objective： To evaluate the protective effects of Reduning Injection （热毒宁注射液, RDN）, a patent Chinese medicine, on lipopolysaccharide （LPS）-induced acute lung injury （ALl） in rats and its underlying mechanisms of action. Methods： Sixty male Sprague-Dawley rats were randomly divided into 6 groups, including normal control, model, dexamethasone （DEX, 5 mg/kg）, RDN-H （720 mg/kg）, RDN-M （360 mg/kg） and RDN-L （180 mg/kg） groups, with 10 rats in each group. Rats were challenged with intravenous injection of LPS 1 h after intraperitoneal treatment with RDN or DEX. At 6 h after LPS challenge, lung tissues and bronchoalveolar lavage fluid （BALF） were collected, and the number of inflammatory cells was determined. The right lungs were collected for histopathologic examination, measurement of gene and protein expressions, superoxide dismutase （SOD） and myeloperoxidase （MPO） activities. Results： In vivo pretreatment of RDN （360, 720 mg/kg） significantly reduced the weight of wet to dry （W/D） ratio of lung, protein content in BALF, and led to remarkable attenuation of LPS-induced histopathological changes in the lungs. Meanwhile, RDN enormously decreased BALF total inflammatory cells, especially neutrophil and macrophage cell numbers. Moreover, RDN increased SOD activity, inhibited MPO activity, alleviated LPS-induced tumor neurosis factor-o~ （TNF-o~） and inducible nitric oxide synthase （iNOS） expression in lung tissues. Furthermore, RDN （720 mg/kg） efficiently weakened nuclear factor- kappa B （NF- K B） gene and protein expression. Conclusion： Anti-inflammatory effects of RDN was demonstrated to be preventing pulmonary neutrophil infiltration, lowering MPO activity, TNF-oL and iNOS gene expression by inhibiting NF- K B activity in LPS-induced ALl.展开更多
Objective:To perform a systematic review to assess the effectiveness and safety of Reduning Injection versus neuraminidase inhibitors in treatment of influenza.Methods:The MEDLINE,Embase,the Cochrane Central Register ...Objective:To perform a systematic review to assess the effectiveness and safety of Reduning Injection versus neuraminidase inhibitors in treatment of influenza.Methods:The MEDLINE,Embase,the Cochrane Central Register of Controlled Trials(CENTRAL),Chinese Bio-medical Literature and Retrieval System(Sinomed),China National Knowledge Infrastructure Database(CNKI),China Science and Technology Journal Database(VIP),Wanfang Data Knowledge Service Platform and ClinicalTrails.gov were systematically searched from inception dates to May 2021 for randomized controlled trials(RCTs)exploring Reduning Injection alone or in combination with neuraminidase inhibitors in patients with influenza.Statistical analysis was performed using RevMan 5.4 and Stata 15.1.The qualities of the involved studies were assessed by the risk of bias according to the Cochrane handbook.The evidence quality of each outcome was evaluated by GRADEpro GDT.Results:Twelve trials with 1,460 patients were included.The included studies had a certain unclear or high risk of bias.Reduning Injection appeared to be more effective in shortening the fever clearance time(MD:-16.20 h,95%CI:-19.40 to-12.99,7 trials,814 patients,I^(2)=94%,very low certainty),fever alleviation time(MD:-4.09 h,95%CI:-4.22 to-3.96,3 trials,366 patients,I^(2)=0%,low certainty),cough alleviation time(MD:-21.34 h,95%CI:-41.56 to-1.11,2 trials,228 patients,I^(2)=89%,very low certainty),fatigue alleviation time(MD:-31.83 h,95%CI:-36.88 to-26.77,2 trials,270 patients,I^(2)=0%,low certainty),sore throat alleviation time(MD:-28.66 h,95%CI:-32.23 to-25.10,1 trial,150 patients,low certainty),and improving the total effective rate(RR:1.15,95%CI:1.06 to 1.25,10 trials,1,074 patients,I^(2)=76%,very low certainty).Besides,Reduning Injection seemed generally safe.Conclusions:This study provided low or very low evidence indicating Reduning Injection may be effective in the treatment of influenza and might be safe.Further rigorously designed studies are needed to confirm the effectiveness and safety of Reduning Injection and support it as a recommendation for influenza.展开更多
目的:采用Meta分析的方法对热毒宁注射液不良反应进行统计分析,评价其临床安全性。方法:检索国家知识基础设施数据库(CNKI)、中国学术期刊数据库(CSPD)、中文科技期刊数据库(CCD),以及PubMed、Cochrane Library、Web of Science,检索公...目的:采用Meta分析的方法对热毒宁注射液不良反应进行统计分析,评价其临床安全性。方法:检索国家知识基础设施数据库(CNKI)、中国学术期刊数据库(CSPD)、中文科技期刊数据库(CCD),以及PubMed、Cochrane Library、Web of Science,检索公开发表的有关热毒宁注射液的临床随机对照试验,时间从建库至2020年4月。由2名研究人员分别独立检索并根据纳入及排除标准筛选文献、提取信息、进行质量评价,采用RevMan 5.3统计软件进行数据分析。同时对不同对照药品、不同用药天数、不同年龄人群的不良反应发生率进行分析。结果:最终符合纳入标准的文献共36篇(37项对照研究),总样本量3917例。Meta分析显示,热毒宁注射液不良反应发生率(3.50%)低于对照组(11.84%),差异有统计学意义(RR=0.31,95%CI为0.24~0.40,Z=9.07,P<0.00001)。亚组分析显示,在利巴韦林亚组(P<0.00001)、用药天数≤5 d亚组(P<0.0001)和>5 d亚组(P=0.0005)以及儿童亚组(P<0.00001)中,热毒宁注射液不良反应发生率均显著低于对照组。与利巴韦林(P<0.00001)、炎琥宁(P=0.01)、痰热清(P=0.02)、双黄连(P=0.001)、头孢曲松(P=0.01)比较,热毒宁注射液有效率均显著高于对照组。结论:热毒宁注射液与利巴韦林比较,不良反应发生率低,疗效好;与炎琥宁、痰热清比较,有较好的临床疗效,但安全性方面没有显著优势。展开更多
文摘【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。
基金Supported by Distinguished Trans-Century Training Program Foundation for the Talents of the State Education Commission,China(No.NCET-12-0678)Natural Science Foundation of Guangdong Province,China(No.S20120011316)+1 种基金Science and Technology Program of Guangzhou,China(No.2012J22000073)Foundation for Distinguished Young Talents in Higher Education of Guangdong,China(No.LYM11023)
文摘Objective： To evaluate the protective effects of Reduning Injection （热毒宁注射液, RDN）, a patent Chinese medicine, on lipopolysaccharide （LPS）-induced acute lung injury （ALl） in rats and its underlying mechanisms of action. Methods： Sixty male Sprague-Dawley rats were randomly divided into 6 groups, including normal control, model, dexamethasone （DEX, 5 mg/kg）, RDN-H （720 mg/kg）, RDN-M （360 mg/kg） and RDN-L （180 mg/kg） groups, with 10 rats in each group. Rats were challenged with intravenous injection of LPS 1 h after intraperitoneal treatment with RDN or DEX. At 6 h after LPS challenge, lung tissues and bronchoalveolar lavage fluid （BALF） were collected, and the number of inflammatory cells was determined. The right lungs were collected for histopathologic examination, measurement of gene and protein expressions, superoxide dismutase （SOD） and myeloperoxidase （MPO） activities. Results： In vivo pretreatment of RDN （360, 720 mg/kg） significantly reduced the weight of wet to dry （W/D） ratio of lung, protein content in BALF, and led to remarkable attenuation of LPS-induced histopathological changes in the lungs. Meanwhile, RDN enormously decreased BALF total inflammatory cells, especially neutrophil and macrophage cell numbers. Moreover, RDN increased SOD activity, inhibited MPO activity, alleviated LPS-induced tumor neurosis factor-o~ （TNF-o~） and inducible nitric oxide synthase （iNOS） expression in lung tissues. Furthermore, RDN （720 mg/kg） efficiently weakened nuclear factor- kappa B （NF- K B） gene and protein expression. Conclusion： Anti-inflammatory effects of RDN was demonstrated to be preventing pulmonary neutrophil infiltration, lowering MPO activity, TNF-oL and iNOS gene expression by inhibiting NF- K B activity in LPS-induced ALl.
基金Supported by the National Major Science and Technology Project of China(No.2017ZX10305501)the Beijing Municipal Hospital Scientific Research Cultivation Program(No.PZ2020016)。
文摘Objective:To perform a systematic review to assess the effectiveness and safety of Reduning Injection versus neuraminidase inhibitors in treatment of influenza.Methods:The MEDLINE,Embase,the Cochrane Central Register of Controlled Trials(CENTRAL),Chinese Bio-medical Literature and Retrieval System(Sinomed),China National Knowledge Infrastructure Database(CNKI),China Science and Technology Journal Database(VIP),Wanfang Data Knowledge Service Platform and ClinicalTrails.gov were systematically searched from inception dates to May 2021 for randomized controlled trials(RCTs)exploring Reduning Injection alone or in combination with neuraminidase inhibitors in patients with influenza.Statistical analysis was performed using RevMan 5.4 and Stata 15.1.The qualities of the involved studies were assessed by the risk of bias according to the Cochrane handbook.The evidence quality of each outcome was evaluated by GRADEpro GDT.Results:Twelve trials with 1,460 patients were included.The included studies had a certain unclear or high risk of bias.Reduning Injection appeared to be more effective in shortening the fever clearance time(MD:-16.20 h,95%CI:-19.40 to-12.99,7 trials,814 patients,I^(2)=94%,very low certainty),fever alleviation time(MD:-4.09 h,95%CI:-4.22 to-3.96,3 trials,366 patients,I^(2)=0%,low certainty),cough alleviation time(MD:-21.34 h,95%CI:-41.56 to-1.11,2 trials,228 patients,I^(2)=89%,very low certainty),fatigue alleviation time(MD:-31.83 h,95%CI:-36.88 to-26.77,2 trials,270 patients,I^(2)=0%,low certainty),sore throat alleviation time(MD:-28.66 h,95%CI:-32.23 to-25.10,1 trial,150 patients,low certainty),and improving the total effective rate(RR:1.15,95%CI:1.06 to 1.25,10 trials,1,074 patients,I^(2)=76%,very low certainty).Besides,Reduning Injection seemed generally safe.Conclusions:This study provided low or very low evidence indicating Reduning Injection may be effective in the treatment of influenza and might be safe.Further rigorously designed studies are needed to confirm the effectiveness and safety of Reduning Injection and support it as a recommendation for influenza.
